BioSpace News Archive

nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today initial nanoMesh™ post-implant inflammation results. Inflammation post-implant of surgical mesh has been associated with scar formation and patient discomfort1.

Emalex Biosciences, Inc. (“Emalex”), today announced positive topline results from its Phase 2b clinical study (D1AMOND Study) evaluating the efficacy and safety of ecopipam (EBS-101), an investigational, first-in-class, dopamine-1 (D1) receptor antagonist, for the treatment of pediatric patients with Tourette Syndrome.

Centene Corporation (NYSE: CNC) announced today it will present at the Wolfe Research Virtual Healthcare Conference, to be held November 17-18, 2021 .

AbbVie will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.

Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, announced that it has priced $600.0 million aggregate principal amount of 1.50% convertible senior notes due 2026.

Boundless Bio today announced that Chief Business Officer, Neil Abdollahian, will present at the Stifel 2021 Virtual Healthcare Conference which will be webcast on Wednesday, November 17th, 2021, at 12:20 p.m. PST/3:20 p.m. EST.

Aridis Pharmaceuticals, Inc. today reported financial and corporate results for its third quarter ended September 30, 2021.

Virpax® Pharmaceuticals, Inc. announced that the National Center for Advancing Translational Sciences at the National Institutes of Health has awarded research and development contracts to support Good Manufacturing Practices production of drug substance and drug product.

MEI Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to zandelisib for the treatment of follicular lymphoma.